Abstract Details

Title A High Number of Relapses and a Delay in Immunosuppressive Therapy are Predictors of Poor Visual Outcomes in LATAM Patients with First-ever NMOSD-related Optic Neuritis

Topic Autoimmune Neurology

Presentation(s) Autoimmune Neurology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 090

Objective To describe and identify independent predictors of poor visual outcomes in Latin American (LATAM) patients who presented with a first-ever neuromyelitis optica spectrum disorder (NMOSD)-related acute optic neuritis (aON).

Background Ethnicity appears to be an influential factor in NMOSD clinical course. However, it is currently unknown what specific factors are associated with poor visual outcomes after a first-ever NMOSD-related aON in LATAM patients.

Design/Methods In this multicenter study, we retrospectively reviewed the medical records of patients with aON as first-ever NMOSD attack who later fulfilled the 2015 diagnostic criteria. Patients from Argentina (n = 48), Ecuador (n = 24), Brazil (n = 22), Venezuela (n = 10), and Mexico (n=8) were included. Demographic, clinical, paraclinical, imaging, and prognostic data were collected. Final visual outcomes were assessed using the Visual Functional System Score (VFSS) of the Expanded Disability Status Scale.

Results A total of 112 patients with first-ever NMOSD-related aON were included. Most of them were women (86.4%), seropositive for aquaporin-4 IgG (69.6%), and non-Caucasian (59.8%). The mean age at disease onset was 38.7±14.2 years. Disease duration at the end of follow-up was 56.3±36.4 months. A higher number of relapses (OR=1.35, 95%-CI: 1.00-1.81; p=0.04) and a longer time between aON onset and preventive treatment (OR=1.03, 95%-CI: 1.00-1.06, p = 0.01) were independent predictors of poor visual outcomes (VFSS ≥4) in the multivariate model.

Conclusions A higher number of relapses as well as a delay in immunosuppression initiation are predictors of final poor visual outcomes in LATAM patients with first-ever NMOSD-related aON.

Authors/Disclosures
Guillermo R. Delgado-Garcia, MD, MSc (University of Calgary - Alberta Health Services) PRESENTER	Dr. Delgado-Garcia has received research support from Consejo Nacional de Ciencia y Tecnologia (Mexico). Dr. Delgado-Garcia has received research support from Consejo Nacional de Ciencia y Tecnologia (Mexico). Dr. Delgado-Garcia has a non-compensated relationship as a Editorial Team Member with Neurology Resident & Fellow Section that is relevant to AAN interests or activities. Dr. Delgado-Garcia has a non-compensated relationship as a Editorial Board Member with Brain and Life en Espanol that is relevant to AAN interests or activities. Dr. Delgado-Garcia has a non-compensated relationship as a Editorial Board Member with Neurology Clinical Practice that is relevant to AAN interests or activities.
Pablo A. Lopez, MD (Merck Serono Argentina)	No disclosure on file
	No disclosure on file
Juan Pablo Pettinicchi, MD (IVAX TEVA)	No disclosure on file
Edgar Patricio Correa Diaz, Sr., MD (Cooperativa IESS-FUT)	Dr. Correa Diaz has nothing to disclose.
Ibis D. Soto, MD	Dr. Soto has nothing to disclose.
Vanessa Daccach Marques	Vanessa Daccach Marques has nothing to disclose.
Veronica A. Tkachuk	Veronica A. Tkachuk has nothing to disclose.
Edgardo Cristiano, MD (Hospital Italiano De Buenos Aires)	Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Liliana B. Patrucco, MD (Hospital Italiano De Buenos Aires)	Dr. Patrucco has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Patrucco has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Patrucco has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Novartis. Dr. Patrucco has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen.
	No disclosure on file
JOSELYN ELIZABETH MIÑO ZAMBRANO, MD (HIBA)	Dr. MIÑO ZAMBRANO has nothing to disclose.
Enrique Gomez Figueroa, MD, MSc	Dr. Gomez Figueroa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen Mexico. Dr. Gomez Figueroa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra Zeneca Mexico. Dr. Gomez Figueroa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Johnson LATAM.
Veronica Rivas	Veronica Rivas has nothing to disclose.
Jose J. Flores-Rivera, MD	Dr. Flores-Rivera has nothing to disclose.
Alejandro E. Caride	No disclosure on file
Juan Ignacio Rojas, MD (Hospital Italiano)	Dr. Rojas has nothing to disclose.
Edgar Carnero Contentti	Edgar Carnero Contentti has nothing to disclose.

��ɫ��

��ɫ��